These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18752063)

  • 21. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
    Storebø OJ; Ramstad E; Krogh HB; Nilausen TD; Skoog M; Holmskov M; Rosendal S; Groth C; Magnusson FL; Moreira-Maia CR; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Forsbøl B; Simonsen E; Gluud C
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD009885. PubMed ID: 26599576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.
    Pelham WE; Aronoff HR; Midlam JK; Shapiro CJ; Gnagy EM; Chronis AM; Onyango AN; Forehand G; Nguyen A; Waxmonsky J
    Pediatrics; 1999 Apr; 103(4):e43. PubMed ID: 10103335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open trial of divalproex sodium in autism spectrum disorders.
    Hollander E; Dolgoff-Kaspar R; Cartwright C; Rawitt R; Novotny S
    J Clin Psychiatry; 2001 Jul; 62(7):530-4. PubMed ID: 11488363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylphenidate in children with ADHD with or without learning disability.
    Williamson D; Murray DW; Damaraju CV; Ascher S; Starr HL
    J Atten Disord; 2014 Feb; 18(2):95-104. PubMed ID: 22628142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
    Stein MA; Sarampote CS; Waldman ID; Robb AS; Conlon C; Pearl PL; Black DO; Seymour KE; Newcorn JH
    Pediatrics; 2003 Nov; 112(5):e404. PubMed ID: 14595084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of citalopram in pervasive developmental disorders.
    Namerow L; Thomas P; Bostic JQ; Prince J; Monuteaux MC
    J Dev Behav Pediatr; 2003 Apr; 24(2):104-8. PubMed ID: 12692455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems.
    Scahill L; McDougle CJ; Aman MG; Johnson C; Handen B; Bearss K; Dziura J; Butter E; Swiezy NG; Arnold LE; Stigler KA; Sukhodolsky DD; Lecavalier L; Pozdol SL; Nikolov R; Hollway JA; Korzekwa P; Gavaletz A; Kohn AE; Koenig K; Grinnon S; Mulick JA; Yu S; Vitiello B;
    J Am Acad Child Adolesc Psychiatry; 2012 Feb; 51(2):136-46. PubMed ID: 22265360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder.
    Gumustas F; Yilmaz I; Yulaf Y; Gokce S; Sabuncuoglu O
    J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):433-439. PubMed ID: 28332851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Extended-Release Methylphenidate Treatment on Cognitive Task Performance in Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
    Pearson DA; Santos CW; Aman MG; Arnold LE; Lane DM; Loveland KA; Mansour R; Ward AR; Casat CD; Jerger S; Schachar RJ; Bukstein OG; Cleveland LA
    J Child Adolesc Psychopharmacol; 2020 Sep; 30(7):414-426. PubMed ID: 32644833
    [No Abstract]   [Full Text] [Related]  

  • 31. A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Huang YS; Yeh CB; Chen CH; Shang CY; Gau SS
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):164-178. PubMed ID: 33395356
    [No Abstract]   [Full Text] [Related]  

  • 32. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases.
    Posey DJ; Puntney JI; Sasher TM; Kem DL; McDougle CJ
    J Child Adolesc Psychopharmacol; 2004; 14(2):233-41. PubMed ID: 15319020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risperidone monotherapy in preschool children with pervasive developmental disorders.
    Masi G; Cosenza A; Mucci M; De Vito G
    J Child Neurol; 2001 Jun; 16(6):395-400. PubMed ID: 11417603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Central nervous system stimulants for secondary attention deficit-hyperactivity disorder after paediatric traumatic brain injury: a rationale and protocol for single patient (n-of-1) multiple cross-over trials.
    Senior HE; McKinlay L; Nikles J; Schluter PJ; Carmont SA; Waugh MC; Epps A; Lloyd O; Mitchell GK
    BMC Pediatr; 2013 May; 13():89. PubMed ID: 23710976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone.
    Masi G; Cosenza A; Mucci M; Brovedani P
    J Clin Psychiatry; 2003 Sep; 64(9):1039-47. PubMed ID: 14628979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
    Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
    Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial.
    King BH; Dukes K; Donnelly CL; Sikich L; McCracken JT; Scahill L; Hollander E; Bregman JD; Anagnostou E; Robinson F; Sullivan L; Hirtz D
    JAMA Pediatr; 2013 Nov; 167(11):1045-52. PubMed ID: 24061784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of medication in pervasive developmental disorders.
    Sloman L
    Psychiatr Clin North Am; 1991 Mar; 14(1):165-82. PubMed ID: 1675463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
    Posey DJ; Wiegand RE; Wilkerson J; Maynard M; Stigler KA; McDougle CJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):599-610. PubMed ID: 17069548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial.
    Efron D; Jarman F; Barker M
    Pediatrics; 1997 Dec; 100(6):E6. PubMed ID: 9382907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.